Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen

Human Gene Therapy Methods

Volumn 23, Issue 5, 2012, Pages 336-345

  Anthony, Karen ^a   Feng, Lucy ^a   Arechavala Gomeza, Virginia ^a   Guglieri, Michela ^b   Straub, Volker ^b   Bushby, Katherine ^b   Cirak, Sebahattin ^a   Morgan, Jennifer ^a   Muntoni, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; ETEPLIRSEN; RNA;

ANTISENSE THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOLECULAR CLONING; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ALTERNATIVE SPLICING; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84874301993     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.117     Document Type: Article

References (30)

1. Aartsma-Rus, A., Bremmer-Bout, M., Janson, A.A., et al. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12(Suppl. 1), S71-77. (Pubitemid 36158776)
2. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., et al. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12, 907-914. (Pubitemid 36504033)
3. Abbs, S., Tuffery-Giraud, S., Bakker, E., et al. (2010). Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscul. Disord. 20, 422-427.
4. Anthony, K., Cirak, S., Torelli, S., et al. (2011). Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134, 3547-3559.
5. Arechavala-Gomeza, V., Graham, I.R., Popplewell, L.J., et al. (2007). Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798-810. (Pubitemid 47502846)
6. Arechavala-Gomeza, V., Kinali, M., Feng, L., et al. (2010). Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul. Disord. 20, 295-301.
7. Bovolenta, M., Scotton, C., Falzarano, M.S., et al. (2012). Rapid, comprehensive analysis of the dystrophin transcript by a custom micro-fluidic exome array. Hum. Mutat. 33, 572-581.
8. Bushby, K., Finkel, R., Birnkrant, D.J., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177-189.
9. Bushby, K.M., Gardner-Medwin, D., Nicholson, L.V., et al. (1993). The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J. Neurol. 240, 105-112. (Pubitemid 23073201)
10. Cacchiarelli, D., Incitti, T., Martone, J., et al. (2011a). miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep. 12, 136-141.
11. Cacchiarelli, D., Legnini, I., Martone, J., et al. (2011b). miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med. 3, 258-265.
12. Chelly, J., Gilgenkrantz, H., Lambert, M., et al. (1990). Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 63, 1239-1248. (Pubitemid 120035072)
13. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
14. Ervasti, J.M. (2007). Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta 1772, 108-117. (Pubitemid 46123911)
15. Ferlini, A., and Rimessi, P. (2012). Exon skipping quantification by real-time PCR. Methods Mol. Biol. 867, 189-199.
16. Goemans, N.M., Tulinius, M., van den Akker, J.T., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
17. Heemskerk, H.A., de Winter, C.L., de Kimpe, S.J., et al. (2009). In vivo comparison of 2¢-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266.
18. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol. 8, 918-928.
19. Klein, C.J., Coovert, D.D., Bulman, D.E., et al. (1992). Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 50, 950-959.
20. Lourbakos, A., Sipkens, J., Beekman, C., et al. (2011). The incidence of revertant and trace dystrophin expression in muscle biopsies of Duchenne Muscular Dystrophy patients with different exon deletions. Neuromuscul. Disord. 21, 643-643.
21. Lu, Q.L., Morris, G.E., Wilton, S.D., et al. (2000). Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. 148, 985-996.
22. Melis, M.A., Cau, M., Muntoni, F., et al. (1998). Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur. J. Paediatr. Neurol. 2, 255-261. (Pubitemid 28553033)
23. Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740. (Pubitemid 37443515)
24. Ramakers, C., Ruijter, J.M., Deprez, R.H., and Moorman, A.F. (2003). Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 339, 62-66. (Pubitemid 36263221)
25. Ruijter, J.M., Ramakers, C., Hoogaars, W.M., et al. (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 37, e45.
26. Spitali, P., Heemskerk, H., Vossen, R.H., et al. (2010). Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne muscular dystrophy. Lab. Invest. 90, 1396-1402.
27. Spitali, P., Rimessi, P., Fabris, M., et al. (2009). Exon skippingmediated dystrophin reading frame restoration for small mutations. Hum. Mutat. 30, 1527-1534.
28. Thanh, L.T., Nguyen, T.M., Helliwell, T.R., and Morris, G.E. (1995). Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 56, 725-731.
29. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
30. Wood, M.J., Gait, M.J., Yin, H. (2010). RNA-targeted splicecorrection therapy for neuromuscular disease. Brain 133, 957-972.